The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high.

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts said at the International AIDS Society conference on HIV science in Rwanda on Monday.

While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to eliminate.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali,

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black women.

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir.

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism.

This story was originally published by The Institute for Public Service Reporting Memphis. Healthcare providers across Tennessee are scrambling to find new funding for HIV prevention following the loss of a critical federal grant.

This 2011 electron microscope image made available by the Centers for Disease Control shows HIV virions. On Wednesday, Sept. 11, 2019, scientists are reporting the first use of the gene-editing tool CRISPR to try to cure a patient's HIV infection by providing blood cells that have been altered to resist the AIDS virus.

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly transform the treatment of older adults living with HIV across Africa. The findings presented at the International AIDS Society Conference on HIV Science in Rwanda on Tuesday shed light on overlooked health